AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 11253562
Drug: Budipine (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Budipine (3 x 20 mg/d)
Trial: 11253562
Drug: Amantadine (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amantadine (3 x 100 mg/d)
Trial: 8173712
Drug: Thrombolytic therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thrombolytic therapy (intravenous tissue plasminogen activator in 561 patients, urokinase in 102 patients, combination of tissue plasminogen activator and urokinase in 147 patients)
Trial: 2946815
Drug: Streptozotocin plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Streptozotocin plus mitomycin C plus 5-FU with 5-FU and streptozotocin administered in five-day courses
Trial: 31365489
Drug: Ringer's acetate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ringer's acetate solution infusion
Trial: 31365489
Drug: Infusions in
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Infusions in normovolemic state
Trial: 18221410
Drug: lumiracoxib 400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: lumiracoxib 400 mg o.d.
Trial: 8527613
Drug: naproxen 500
RxNorm normalized name: naproxen 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: naproxen 500 mg b.d.
Trial: 18221410
Drug: ibuprofen 800
RxNorm normalized name: ibuprofen 800 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ibuprofen 800 mg t.d.s.
Trial: 12615747
Drug: ACE inhibitors
RxNorm normalized name: ACE INHIBITORS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ACE inhibitors (general)
Trial: 8249554
Drug: Intramuscular (im)
RxNorm normalized name: intramuscular immunoglobulin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular (im) morphine
Trial: 24955739
Drug: Oral valproic
RxNorm normalized name: Valproic Acid
DrugBank: Valproic acid (DB00313)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral valproic acid (VPA) 500mg once daily for 1 year
Trial: 12695832
Drug: Contrast injection
RxNorm normalized name: Contrased
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Contrast injection at 0.1 ml/kg body weight s(‐1) over 21 s without flush (Group 1)
Trial: 12695832
Drug: Contrast injection
RxNorm normalized name: Contrased
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Contrast injection at 0.1 ml/kg body weight s(‐1) over 21 s with a 30-ml flush (Group 2)
Trial: 12695832
Drug: Contrast injection
RxNorm normalized name: Contrased
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Contrast injection at 0.07 ml/kg body weight s(‐1) over 30 s without flush (Group 3)
Trial: 12695832
Drug: Contrast injection
RxNorm normalized name: Contrased
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Contrast injection at 0.07 ml/kg body weight s(‐1) over 30 s with a 30-ml flush (Group 4)
Trial: 12695832
Drug: Higher injection
RxNorm normalized name: BENZOCAINE 50 mg in 1 mL TOPICAL GEL [HIGHER CONTROL Male Climax Control Lubricating]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Higher injection rate protocols (Groups 1 and 2)
Trial: 1661447
Drug: Standard Heparin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard Heparin (SH)
Trial: 30012389
Drug: Acupuncture treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acupuncture treatment (n=47)
Trial: 27358159
Drug: Intra-articular injection
RxNorm normalized name: PHOSPHORUS P-32 5 mCi in 1 mL INTRA-ARTICULAR INJECTION, SUSPENSION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intra-articular injection of hyaluronic acid (HA)
Trial: 27358159
Drug: Intra-articular injection
RxNorm normalized name: PHOSPHORUS P-32 5 mCi in 1 mL INTRA-ARTICULAR INJECTION, SUSPENSION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intra-articular injection of oxygen ozone (O2O3)
Trial: 27358159
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of hyaluronic acid (HA) and oxygen ozone (O2O3)
Trial: 24776953
Drug: Alternative monotherapy
RxNorm normalized name: yellow fever virus strain 17D-204 live antigen
DrugBank: Yellow fever vaccine (DB10805)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alternative monotherapy with a second AED (Group A)
Trial: 24776953
Drug: Add-on treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Add-on treatment with a second AED (Group B)
Trial: 22570370
Drug: Adherence and
RxNorm normalized name: dressing,low adherence and wound contact materials
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adherence and Intensification of Medications intervention
Trial: 17456583
Drug: Oseltamivir (all
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oseltamivir (all doses)
Trial: 12487226
Drug: Montelukast (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Montelukast (5 mg for ages 6 to < 14 years; 10 mg for > 14 years)
Trial: 9660559
Drug: Dynamic k-space
RxNorm normalized name: Effer-K
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dynamic k-space filling with bolus chase 3D MRDSA using a 25-ml gadolinium dose and a multiple-phase 3D fast gradient-echo sequence.
Trial: 2539648
Drug: IE (ifosfamide,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IE (ifosfamide, 1.5 g/m2, days 1 through 5; etoposide, 120 mg/m2, days 3 through 5)
Trial: 2539648
Drug: CAV (cyclophosphamide,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CAV (cyclophosphamide, 600 mg/m2, days 1 and 2; doxorubicin, 50 mg/m2, day 1; vincristine, 2 mg, day 1)
Trial: 2539648
Drug: PE (cisplatin,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PE (cisplatin, 90 mg/m2, day 1; etoposide, 150 mg/m2, days 3 through 5)
Trial: 2539648
Drug: IAV (ifosfamide,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IAV (ifosfamide, 2 g/m2, days 1 to 5; doxorubicin, 25 mg/m2, days 1 and 2; vincristine, 2 mg, day 1)
Trial: 2539648
Drug: PE or
RxNorm normalized name: M-End PE Oral Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PE or JE (carboplatin, 300 mg/m2, day 1; etoposide, 120 mg/m2, days 1 to 3)
Trial: 362519
Drug: Oral dose
RxNorm normalized name: Exactamed Oral Dose Syringe 35cc
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral dose of 1 g twice daily for one day
Trial: 362519
Drug: Single dose
RxNorm normalized name: Citrucel Single Dose Packets (Orange)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose of 50 mg/kg
Trial: 362519
Drug: Higher dosage
RxNorm normalized name: osage orange pollen extract
DrugBank: Maclura pomifera pollen (DB10988)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Higher dosage regime (1 g twice daily)
Trial: 30825563
Drug: Traditional debridement
RxNorm normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Traditional debridement therapy
Trial: 28093383
Drug: Semi-standardised individual
RxNorm normalized name: Semi-Daonil
DrugBank: Glyburide (DB01016)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Semi-standardised individual acupuncture inspired by Traditional Chinese Medicine
Trial: 11181985
Drug: Active NCPAP
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active NCPAP therapy
Trial: 11181985
Drug: Sub-therapeutic NCPAP
RxNorm normalized name: Moisturel Therapeutic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sub-therapeutic NCPAP therapy
Trial: 7851269
Drug: Diabetic subjects
RxNorm normalized name: Diabetic Tussin EX
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diabetic subjects (mean glomerular filtration rate 216 ml/min)
Trial: 7851269
Drug: Diabetic subjects
RxNorm normalized name: Diabetic Tussin EX
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diabetic subjects (corrected for body size, mean glomerular filtration rate 165.6 ml/min per 1.73 m2)
Trial: 7851269
Drug: Diabetic subjects
RxNorm normalized name: Diabetic Tussin EX
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diabetic subjects (albumin excretion median 61 mg/day)
Trial: 3072940
Drug: HR-6 solutions
RxNorm normalized name: nitroglycerin 0.6 MG/HR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HR-6 solutions containing adenosine triphosphate (0.5 or 5 mg/ml)
Trial: 29505742
Drug: Delayed rotator
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Delayed rotator cuff repair after 6 months of nonoperative treatment (Group 2, n = 34)
Trial: 20736152
Drug: Darunavir/ritonavir (800/100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Darunavir/ritonavir (800/100 mg once daily) alone (DRVrMono)
Trial: 2888302
Drug: Carvedilol, 50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carvedilol, 50 mg
Trial: 2888302
Drug: Atenolol, 50
RxNorm normalized name: Atenolol, 50 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atenolol, 50 mg
Trial: 2888302
Drug: Carvedilol, 25
RxNorm normalized name: Carvedilol, 25 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carvedilol, 25 mg
Trial: 23558890
Drug: Tiotropium 18
RxNorm normalized name: TIOTROPIUM 18MCG CAP,INHL,6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tiotropium 18 μg daily
Trial: 16620590
Drug: Intramuscular revaccination
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular revaccination (10 microg per dose)
Trial: 16620590
Drug: Intradermal revaccination
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intradermal revaccination (2 microg per dose)
Trial: 16310902
Drug: Booster dose
RxNorm normalized name: SARS-COV-2 (COVID-19) Vaccine, mRNA (Moderna) 50 MCG/0.5 ML Intramuscular Suspension [MODERNA COVID-19 VACCINE BOOSTER DOSE]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Booster dose (5 microg) for those who lost seroprotection
Trial: 10907947
Drug: 5-fluorouracil (450
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5-fluorouracil (450 mg/m2 i.v. weekly) and levamisole (150 mg p.o. every two weeks)
Trial: 10907947
Drug: Leucovorin (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Leucovorin (20 mg/m2 i.v.), 5-fluorouracil and levamisole
Trial: 9362435
Drug: Clodronate, 300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clodronate, 300 mg/day intravenously (i.v.)
Trial: 9362435
Drug: Oral clodronate,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral clodronate, 1600-3200 mg/day
Trial: 9362435
Drug: Alendronate, 5
RxNorm normalized name: Alendronate, 5 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alendronate, 5 mg i.v. as a single infusion
Trial: 9362435
Drug: Alendronate, 40
RxNorm normalized name: Alendronate, 40 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alendronate, 40 mg orally/day
Trial: 27725911
Drug: Induction chemotherapy
RxNorm normalized name: human sputum, Bordetella pertussis infected
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Induction chemotherapy (IC) with docetaxel (DOC) plus nedaplatin (NDP) followed by IMRT concurrent with weekly NDP
Trial: 12947431
Drug: 5 g
RxNorm normalized name: 15 g/31 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 g of guar gum (3.6 g galactomannan)
Trial: 12947431
Drug: 5 g
RxNorm normalized name: 15 g/31 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 g of fructose
Trial: 12947431
Drug: 5 g
RxNorm normalized name: 15 g/31 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 g of guar gum + 5 g of fructose
Trial: 12947431
Drug: Control (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (50 g of available carbohydrate from maltodextrin and white bread)
Trial: 9249631
Drug: Topical metronidazole
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical metronidazole (95% collagen and 5% metronidazole device) combined with mechanical treatment
Trial: 9249631
Drug: Mechanical treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mechanical treatment alone
Trial: 3828955
Drug: L‐phenylalanine mustard
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L‐phenylalanine mustard (L‐PAM) and 5‐fluorouracil (5‐FU) with tamoxifen
Trial: 3828955
Drug: L‐phenylalanine mustard
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L‐phenylalanine mustard (L‐PAM) and 5‐fluorouracil (5‐FU) without tamoxifen
Trial: 23752849
Drug: Intraoperative ozone
RxNorm normalized name: ozone
DrugBank: Ozone (DB12510)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intraoperative ozone and postoperative millimeter wave therapy
Trial: 12954574
Drug: 5‐fluorouracil [450
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5‐fluorouracil [450 mg/m(2) intravenous (i.v.) bolus on days 1‐5] and levamisole (150 mg orally for 3 days, every 14 days for 6 months)
Trial: 12954574
Drug: 6‐S‐leucovorin (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6‐S‐leucovorin (100 mg/m(2) i.v. bolus on days 1‐5) followed by 5‐fluorouracil (370 mg/m(2) i.v. bolus on days 1‐5), plus levamisole (as arm A), every 4 weeks for six cycles
Trial: 1347757
Drug: Lovastatin (20‐80
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lovastatin (20‐80 mg daily)
Trial: 2863220
Drug: Nifedipine (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nifedipine (10 mg three times a day)
Trial: 30035578
Drug: Alcohol targeting
RxNorm normalized name: Alcohol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Alcohol targeting a blood alcohol concentration (BAC) of .08 g%
Trial: 21153822
Drug: Zibotentan 10
RxNorm normalized name: Zibotentan
DrugBank: Zibotentan (DB06629)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zibotentan 10 mg plus pemetrexed 500 mg/m²
Trial: 21153822
Drug: Placebo plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo plus pemetrexed 500 mg/m²
Trial: 8227863
Drug: Aqueous beclomethasone
RxNorm normalized name: Pen-Aqueous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aqueous beclomethasone dipropionate (168 micrograms twice daily)
Trial: 8227863
Drug: Triamcinolone acetonide
RxNorm normalized name: Triamcinolone Acetonide
DrugBank: Triamcinolone (DB00620)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Triamcinolone acetonide (220 micrograms twice daily)
Trial: 3524050
Drug: Live cold-adapted
RxNorm normalized name: Typhoid Vaccine Live
DrugBank: Typhoid Vaccine Live (DB11050)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Live cold-adapted recombinant bivalent vaccine of influenza type A
Trial: 14566214
Drug: Matching placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo patches
Trial: 12584575
Drug: 21 mg
RxNorm normalized name: aspirin 421 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 21 mg nicotine patch
Trial: 28148501
Drug: Enalapril-folic acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enalapril-folic acid (10 mg enalapril and 0.8 mg folic acid)
Trial: 26254941
Drug: Self-Regulation Treatment
RxNorm normalized name: corticotropin
DrugBank: Corticotropin (DB01285)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Self-Regulation Treatment Group (n = 136)
Trial: 26254941
Drug: Self-Efficacy Treatment
RxNorm normalized name: corticotropin
DrugBank: Corticotropin (DB01285)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Self-Efficacy Treatment Group (n = 138)
Trial: 21088912
Drug: Daily diary
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily diary for 7 days
Trial: 17217572
Drug: 500 mg
RxNorm normalized name: bran 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500 mg Ca/d
Trial: 8154971
Drug: Low-dose intravenous
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose intravenous ganciclovir for 3 weeks (group 2, n = 24)
Trial: 8154971
Drug: Seven doses
RxNorm normalized name: Sevenfact
DrugBank: Coagulation factor VIIa Recombinant Human (DB00036)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Seven doses of intravenous immunoglobulin for 6-week periods (group 1, n = 27)
Trial: 3042356
Drug: urapidil (60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: urapidil (60 to 120 mg/day)
Trial: 26298795
Drug: Nightly dosing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nightly dosing with 10 mg zolpidem (QHS-10)
Trial: 26298795
Drug: Nightly dosing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nightly dosing with 5 mg zolpidem (QHS-5)
Trial: 26298795
Drug: Intermittent dosing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intermittent dosing with 10 mg zolpidem (IDS-10)
Trial: 26298795
Drug: Partial reinforcement
RxNorm normalized name: rosin partially dimerized glycerol ester
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Partial reinforcement dosing with 10 mg zolpidem (PRS-10)
Trial: 23246610
Drug: Treatment indicated
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment indicated for schizophrenia (specific treatments not detailed in the abstract)
Trial: 16930215
Drug: Post-discontinuation of
RxNorm normalized name: post oak pollen extract
DrugBank: Quercus stellata pollen (DB10888)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Post-discontinuation of alcohol at 0.1% BAL
Trial: 12966595
Drug: Ferrous sulfate
RxNorm normalized name: Ferrous Sulfate
DrugBank: Ferrous fumarate (DB14491)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ferrous sulfate 300 mg twice daily
Trial: 10894865
Drug: Cisplatin/continuous infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cisplatin/continuous infusion doxorubicin (regimen B)
Trial: 9410281
Drug: Bronchodilator inhalation
RxNorm normalized name: Bronchodil
DrugBank: Reproterol (DB12846)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bronchodilator inhalation (0.2 mg fenoterol)
Trial: 9410281
Drug: Patients unresponsive
RxNorm normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients unresponsive to beta‐agonist (delta FEVI <= 15%)
Trial: 1589588
Drug: 1.5 mg
RxNorm normalized name: boron 1.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.5 mg RS 86 (cholinergic agonist)
Trial: 27856202
Drug: Joint National
RxNorm normalized name: ActivOn Joint & Muscle
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Joint National Committee (JNC) 7 compliant treatment with intensive BP goals (<120/80 mm Hg)
Trial: 16386539
Drug: Cyclosporine (G-1)
RxNorm normalized name: Cyclosporine
DrugBank: Cyclosporine (DB00091)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cyclosporine (G-1)
Trial: 16386539
Drug: Tacrolimus (G-2)
RxNorm normalized name: Tacrolimus
DrugBank: Tacrolimus (DB00864)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tacrolimus (G-2)
Trial: 7751412
Drug: Indapamide 1.25
RxNorm normalized name: indapamide 1.25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Indapamide 1.25 mg/day
Trial: 2647556
Drug: Aspirin alone
RxNorm normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Aspirin alone (330 mg 3 times daily)
Trial: 2647556
Drug: Aspirin plus
RxNorm normalized name: Aspirin Plus Antacid Extra Strength
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin plus dipyridamole (75 mg 3 times daily)
Trial: 26411993
Drug: Insulin-treated patients
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Insulin-treated patients
Trial: 29525823
Drug: Feracrylum 1%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Feracrylum 1% solution (FS)
Trial: 24786017
Drug: Sildenafil fine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sildenafil fine granule 50 mg
Trial: 24786017
Drug: Sildenafil tablet
RxNorm normalized name: Sildenafil Tablets
DrugBank: Sildenafil (DB00203)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sildenafil tablet 50 mg
Trial: 18333865
Drug: Cotrimoxazole (960
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cotrimoxazole (960 mg b.i.d.; 160 mg trimethoprim and 800 mg sulfamethoxazole)
Trial: 18333865
Drug: Tenofovir (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tenofovir (300 mg q.d.)
Trial: 15940615
Drug: Infliximab 4-5
RxNorm normalized name: Infliximab
DrugBank: Infliximab (DB00065)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Infliximab 4-5 mg/kg
Trial: 12915643
Drug: Testosterone treatment
RxNorm normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Testosterone treatment (500 mg, 250 mg, and 250 mg im testosterone esters)
Trial: 10834413
Drug: Insulin aspart
RxNorm normalized name: Insulin Aspart
DrugBank: Insulin aspart (DB01306)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Insulin aspart (IAsp) and Regular human insulin (HI)
Trial: 12062374
Drug: Omega-3 PUFA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omega-3 PUFA (1.65 g per day)
Trial: 10214573
Drug: ADCON-L (Adhesion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ADCON-L (Adhesion Control in a Barrier Gel)
Trial: 7890391
Drug: Bivalent formulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bivalent formulation (vibrio cholerae CVD 103‐HgR and Salmonella typhi Ty21a)
Trial: 7890391
Drug: CVD 103‐HgR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CVD 103‐HgR followed by two doses of killed Escherichia coli K‐12 placebo
Trial: 140029
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of a diuretic and rauwolfia serpentina
Trial: 23348842
Drug: Kava (120
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Kava (120 mg of kavalactones per day, titrated to 240 mg if non-response)
Trial: 21753154
Drug: Vismodegib 150
RxNorm normalized name: vismodegib 150 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vismodegib 150 mg QD (n = 23)
Trial: 21753154
Drug: Vismodegib 150
RxNorm normalized name: vismodegib 150 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vismodegib 150 mg TIW (n = 22)
Trial: 21753154
Drug: Vismodegib 150
RxNorm normalized name: vismodegib 150 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vismodegib 150 mg QW (n = 22)
Trial: 21753154
Drug: Vismodegib 150
RxNorm normalized name: vismodegib 150 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vismodegib 150 mg QD (loading dose for 11 days)